Q4 guidance for flat revenue and EPS of $0.12-$0.20 suggests continued headwinds from Middle East disruptions. Monitor the Q4 earnings call for updates on Middle East activity recovery and international project momentum, which are key to a sustained turnaround.
Price Chart
Executive Summary
Core Laboratories reported Q3 2026 revenue of $132.1M, up 6% sequentially but down 1.8% YoY, and GAAP EPS of $0.12. Ex-items EPS was $0.16, in line with the $0.16 consensus. The company guided Q4 2026 revenue of $128.5M-$134.5M and EPS of $0.12-$0.20, with management noting continued Middle East disruptions and a flat sequential revenue outlook. Sequential improvement was driven by both segments, but YoY comparisons remain negative across most metrics.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $132.1M, up 6% sequentially, down 1.8% YoY
- GAAP EPS of $0.12; ex-items EPS of $0.16, in line with $0.16 consensus
- Operating income ex-items of $12.6M, up 35% sequentially but down 24% YoY
- Reservoir Description revenue $84.3M, up 7% sequentially, down 4% YoY
- Production Enhancement revenue $47.8M, up 4% sequentially, up 3% YoY
- Free cash flow of $1.7M in Q3 2026
- Repurchased 87,873 shares for $1.1M in Q3
- Q4 2026 guidance: revenue $128.5M-$134.5M, EPS $0.12-$0.20
- Net debt of $93.4M as of Sep 30, 2026, down $0.2M sequentially
- Quarterly dividend of $0.01 per share maintained
Financial Impact
Revenue $132.1M, GAAP net income $5.4M, ex-items EPS $0.16 in line with consensus
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Reservoir Description | $84.3M | -4.4% |
| Production Enhancement | $47.8M | +3.2% |
Risk Factors
- Ongoing Middle East geopolitical conflicts disrupting client activity and project timelines
- YoY revenue and earnings declines persist across most metrics
- Q4 guidance implies potentially flat to slightly lower revenue sequentially
- Elevated working capital from higher receivables and inventory
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-436200 |
| Document: clb-20261028.htm | 0001193125-26-436200 |
| Document: 0001193125-26-436200-index-headers.html | 0001193125-26-436200 |
| Document: 0001193125-26-436200-index.html | 0001193125-26-436200 |
| Document: 0001193125-26-436200.txt | 0001193125-26-436200 |
| 8-K Data (Synthetic) | 0001193125-26-436200 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 2d ago | 8-K | $10.40 | awaiting T+60 | awaiting T+60 | $10.64 (+2.31%) |
Aug 4, 2026 12w ago | Insider Buy | $11.22 $10.33 | ▼ −7.93% | ▼ −8.31% | $10.64 (−5.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers